Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]

Treating RET alterations with novel therapy BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Treating RET alterations with novel therapy BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

AKT inhibitors in research and application

Dr Brian Schwartz - ArQule, Burlington, USA

AKT inhibitors in research and application ( Dr Brian Schwartz - ArQule, Burlington, USA )

Reducing recurrence of advanced melanoma with pembrolizumab

Prof Alex Eggermont - Paris-Sud University, Paris, France

Reducing recurrence of advanced melanoma with pembrolizumab ( Prof Alex Eggermont - Paris-Sud University, Paris, France )

Results of KEYNOTE-054; melanoma patients treated with pembrolizumab.

Prof Alex Eggermont - Paris-Sud University, Paris, France

Results of KEYNOTE-054; melanoma patients treated with pembrolizumab. ( Prof Alex Eggermont - Paris-Sud University, Paris, France )

Management of marker negative stage II testicular cancer

Dr Christian Kollmannsberger - University of British Columbia, Vancouver, Canada

Management of marker negative stage II testicular cancer ( Dr Christian Kollmannsberger - University of British Columbia, Vancouver, Canada )

Editor's Choice for February 2018

Prof Gordon McVie - Founding Editor, ecancer

Editor's Choice for February 2018 ( Prof Gordon McVie - Founding Editor, ecancer )

The EMA perspective on drug approval process in the era of precision medicine

Jorge Camarero - Spanish Agency of Medicines and Medical Services, Spain

The EMA perspective on drug approval process in the era of precision medicine ( Jorge Camarero - Spanish Agency of Medicines and Medical Services, Spain )

Expert insight: Metastatic hormone sensitive prostate cancer latest

Professor Karim Fizazi and Professor Nicholas James

Expert insight: Metastatic hormone sensitive prostate cancer latest ( Professor Karim Fizazi and Professor Nicholas James )

Comment: Urothelial cancer research from ASCO GU 2018

Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA

Comment: Urothelial cancer research from ASCO GU 2018 ( Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA )

VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and...

Dr Lisa Pickering - The Royal Marsden NHS Foundation Trust, London, UK

VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis ( Dr Lisa Pickering - The Royal Marsden NHS Foundation Trust, London, UK )

Genomic profiling of muscle invasive bladder cancer to predict response to...

Dr David Miyamoto - Massachusetts General Hospital, Boston, USA

Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy ( Dr David Miyamoto - Massachusetts General Hospital, Boston, USA )

Crizotinib for advanced papillary renal cell carcinoma with MET mutations or...

Prof Patrick Schöffski - The Katholieke Universiteit Leuven, Leuven, Belgium

Crizotinib for advanced papillary renal cell carcinoma with MET mutations or amplification ( Prof Patrick Schöffski - The Katholieke Universiteit Leuven, Leuven, Belgium )

More from ecancer